ACTRN12607000260426已完成1 期
A Phase 1 Single-Center, Open-Label Study to Evaluate the Safety and Pharmacokinetics of a Candidate Topical Antimicrobial (NEO101) among Healthy Adult Men
eosil, Inc0 个研究点目标入组 5 人开始时间: 2007年5月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 40 Years（—）
- 性别
- Male
入选标准
- •Subjects, in general good health, compliant with (defined) birth control.
排除标准
- •Subjects have concomitant dermatologic or medical condition(s) which may interfere with the investigator's ability to evaluate the subject's response to the study drug, have clinical evidence of active cutaneous infection, have had skin or soft tissue infection with S. aureus within 30 days prior to enrollment, have documented disruption of the nasal or facial bones, have atopic dermatitis/eczema, allergic rhinitis, nasal polyps or nasal piercings, have a history of hypersensitivity or allergic reactions to parabens, sodium sulfite or any other ingredient in the formulation.
研究者
相似试验
已完成
1 期
A Study to Evaluate Single Doses of Dihydroergotamine Mesylate Inhalation Powder and Dihydroergotamine Mesylate Intravenous in Healthy Adult SubjectsACTRN12623001201662Syneos Health New Zealand Ltd28
已完成
1 期
A Phase 1, Single-Center, Open-label Study to Evaluate the Pharmacokinetics of PRN1008 in Healthy Male and Female VolunteersInflammatory and Immune System - Autoimmune diseasesSystemic Lupus ErythematosusRheumatoid ArthritisInflammatory Bowel DiseaseACTRN12615000614594Clinical Network Services (CNS) Pty Ltd12
已完成
1 期
A Phase 1, Single-Center, Open-label Study to Evaluate the Safety and Pharmacokinetics of Two Tablet Formulations of PRN1008Rheumatoid ArthritisACTRN12616001557426Principia Biopharma Australia Pty Ltd14
未知
1 期
A Phase I, Open Label, Single-centre Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055 Administered Orally to Japanese Patients With Advanced Solid TumoursCancerJPRN-jRCT2080220891AstraZeneca
尚未招募
1 期
A Phase I/II open-label study at a single research center to evaluate the safety, tolerability, and effects of RGX-111 gene therapy given directly into the central nervous system in subjects with severe mucopolysaccharidosis type IMucopolysaccharidosis type IMucopolysaccharidosis IE76.0C16.320.565.202.715.640RBR-758cbnHospitais de Clínicas de Porto Alegre